伊利诺伊州 的 肺癌 临床试验
伊利诺伊州 有 65 项针对 肺癌 的研究正在招募参与者。
伊利诺伊州 的城市
- Chicago43 项研究
- Evanston19 项研究
- Cicero18 项研究
- Waukegan16 项研究
- Peoria13 项研究
- Springfield13 项研究
- Naperville13 项研究
- Decatur11 项研究
- Joliet11 项研究
- Arlington Heights10 项研究
- North Peoria10 项研究
- Bloomington10 项研究
- Galesburg10 项研究
- Aurora10 项研究
- Danville9 项研究
- Champaign9 项研究
- Elgin8 项研究
- Charleston8 项研究
- Rockford5 项研究
- Carbondale4 项研究
官方研究文本（英文）
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- University of Illinois Chicago, Chicago
- Illinois Cancer Specialists, Niles
招募中3 期
18 至 100 岁 · 所有性别 · 更新于 2026年11月13日 · NCT05920356A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Cancer Care Specialists of Illinois - Cancer Care Center of O'Fallon, Decatur
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月13日 · NCT07063745Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Rush University Medical Center, Chicago
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT07100080This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Endeavor Health, Elmhurst
- Hope and Healing Cancer Services, Hinsdale
- Advocate Medical Group - Libertyville Oncology, Libertyville
- 以及另外 4 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Northwestern University, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- Northwestern Medicine Cancer Center Delnor, Geneva
- 以及另外 8 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Advocate Good Shepherd Hospital, Barrington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- 以及另外 42 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT04267848Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- Captain James A. Lovell Federal Health Care Center, North Chicago
招募中
50 至 80 岁 · 所有性别 · 更新于 2026年11月12日 · NCT07168993Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- 以及另外 26 项
招募中3 期
70 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06096844A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- North Shore University Health System ( Site 4014), Evanston
- Accellacare of Duly ( Site 4005), Lisle
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月10日 · NCT06312137A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Hinsdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月10日 · NCT07099898Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- University of Illinois Cancer Center, Chicago
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月6日 · NCT04198766A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Affiliated Oncologists, LLC, Chicago Ridge
- City of Hope® Cancer Center Chicago, Zion
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月5日 · NCT06793215Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- 以及另外 52 项
招募中观察性研究欢迎健康志愿者
40 至 75 岁 · 所有性别 · 更新于 2026年11月4日 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- 以及另外 34 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT04181060A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
- Springfield Clinic Main Campus, Springfield
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT06119581Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Illinois Cancer Specialists, Arlington Heights
- University of Illinois Hospital and Health Sciences Systems, Chicago
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月2日 · NCT07185997Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年10月30日 · NCT05974150Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- UC Comprehensive Cancer Center at Silver Cross, New Lenox
- University of Chicago Medicine-Orland Park, Orland Park
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月29日 · NCT06287775Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月27日 · NCT07782359A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月26日 · NCT06172478Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- Edward Hines Jr. VA Hospital, Hines, IL, Hines
招募中
18 岁及以上 · 所有性别 · 更新于 2026年10月23日 · NCT02984761Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Northwestern Memorial Hospital, Chicago
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月23日 · NCT06922591A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月22日 · NCT07154290Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Chicago
招募中2 期
18 至 95 岁 · 所有性别 · 更新于 2026年10月21日 · NCT05061550Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Northwestern Memorial Hospital, Chicago
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月21日 · NCT06810544DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
- Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital), Chicago
招募中观察性研究
18 至 75 岁 · 所有性别 · 更新于 2026年10月21日 · NCT05671887Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
- City of Hope at Chicago, Zion
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月16日 · NCT07288034Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Illinois Cancer Specialists, Niles
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月14日 · NCT06712355Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- 以及另外 15 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT07393555Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT06293898A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- University of Illinois Medical Center, Chicago
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT07128199Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Hope and Healing Clinical Research, Hinsdale
- Hope and Healing Clinical Research, New Lenox
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月9日 · NCT07476287Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- 以及另外 35 项
招募中2 期
18 Minutes · 所有性别 · 更新于 2026年10月9日 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- Illinois CancerCare-Bloomington, Bloomington
- 以及另外 49 项
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月9日 · NCT06616584Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Hope and Healing Clinical Research, Hinsdale
- Hope and Healing Clinical Research, New Lenox
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月8日 · NCT07489066Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Illinois Cancer Specialists, Arlington Heights
- Illinois CancerCare - Bloomington, Bloomington
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- 以及另外 11 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月8日 · NCT07222566Empathic Communication Skills (ECS) Training
- Advocate Health Care Network, Libertyville
招募中欢迎健康志愿者
18 至 100 岁 · 所有性别 · 更新于 2026年10月7日 · NCT05456841A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- University of Illinois Hospital & Health Sciences System ( Site 0044), Chicago
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT07286149A Registry for People With Lung Cancer
- Rush University Medical Center (Data collection only), Chicago
- Endeavor Health, Evanston
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06424327Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- OSF Saint Francis Medical Center, Peoria
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月3日 · NCT06343402数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。